Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora, Paul Martin; Glatzer, Markus; Belderbos, José; Besse, Benjamin; Blackhall, Fiona; Califano, Raffaele; Cappuzzo, Federico; de Marinis, Filippo; Dziadziuszko, Rafal; Felip, Enriqueta; Faivre-Finn, Corinne; Früh, Martin; Garrido, Pilar; Le Pechoux, Cecila; McDonald, Fiona; Nestle, Ursula; Novello, Silvia; O'Brien, Mary; Paz Ares, Luis; Peeters, Stephanie; ... (2019). Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and oncology, 133, pp. 163-166. Elsevier 10.1016/j.radonc.2018.12.014

[img] Text
1-s2.0-S0167814018336533-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (906kB) | Request a copy

BACKGROUND Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial. METHODS We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology. RESULTS The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age and good response to chemotherapy. PCI was recommended by the majority of experts for non-elderly fit patients who had at least a partial response (PR) to chemotherapy (for complete remission (CR) 85% of radiation oncologists and 69% of medical oncologists, for PR: 85% of radiation oncologists and 54% of medical oncologists). For patients with stable disease after chemotherapy, PCI was recommended by 6 out of 13 (46%) radiation oncologists and only 3 out of 13 medical oncologists (23%). For elderly fit patients with CR, a majority recommended PCI (62%) and no consensus was reached for patients with PR. CONCLUSION European radiation and medical oncologists specializing in lung cancer recommend PCI in selected patients and restrict its use primarily to fit, non-elderly patients who responded to chemotherapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

26 Jul 2019 10:05

Last Modified:

05 Nov 2019 14:18

Publisher DOI:

10.1016/j.radonc.2018.12.014

PubMed ID:

30935574

Uncontrolled Keywords:

ESTRO Expert opinion IASLC PCI Small cell lung cancer Stage IV

BORIS DOI:

10.7892/boris.131352

URI:

https://boris.unibe.ch/id/eprint/131352

Actions (login required)

Edit item Edit item
Provide Feedback